U.S. FDA Accepts Takeda's Zasocitinib New Drug Application for Moderate-to-Severe Plaque Psoriasis Under Priority Review

The U.S. Food and Drug Administration (FDA) has accepted Takeda's New Drug Application (NDA) for zasocitinib (TAK-279) under Priority Review for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational oral tyrosine kinase 2 (TYK2) inhibitor, with the acceptance based on pivotal Phase 3 data showing rapid, durable, and consistent skin clearance.